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ABSTRACT
Species differences in drug metabolism and disposition can con-
found the extrapolation of in vivo PKdata toman and also profoundly
compromise drug efficacy studies owing to differences in pharma-
cokinetics, in metabolites produced (which are often pharmacolog-
ically active), and in differential activation of the transcription factors
constitutive androstane receptor (CAR) and pregnane X receptor
(PXR), which regulate the expression of such enzymes as P450s and
drug transporters. These differences have gained additional impor-
tance as a consequence of the use of genetically modified mouse
models for drug-efficacy testing and also patient-derived xeno-
grafts to predict individual patient responses to anticancer drugs. A
number of humanized mouse models for cytochrome P450s, CAR,
and PXR have been reported. However, the utility of these models
has been compromised by the redundancy in P450 reactions across
gene families, whereby the remaining murine P450s can metabolize
the compounds being tested. To remove this confounding factor and
create amousemodel that more closely reflects human pathways of
drug disposition, we substituted 33 murine P450s from the major
gene families involved in drug disposition, togetherwith Car and Pxr,
for humanCAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4,
and CYP3A7. We also created a mouse line in which 34 P450s were
deleted from the mouse genome. Using model compounds and
anticancer drugs, we demonstrated how these mouse lines can be
applied to predict drug-drug interactions in patients and discuss
here their potential application in the more informed design of
clinical trials and the personalized treatment of cancer.
Introduction
Data obtained during preclinical development often fail their extrap-
olation to the clinic; this is a major reason for the high rate of attrition in
drug development (Kola and Landis, 2004; Kola, 2008). In addition,
once a drug has reached the clinic, the capacity to improve drug treatment
regimens by clinical trial is limited both by their expense and the
numerous possible trial designs, particularly when drug combinations are
being tested. Therefore, an urgent need exists to develop better in vivo
models more predictive of human drug response (Kersten et al., 2017).
Studies in rodents play a pivotal role in elucidating human responses to
drugs and environmental chemicals. They are also of critical importance
in furthering our understanding of human disease by serving as models
for drug efficacy testing and, more recently, as a model system for the
personalization of the treatment of diseases such as cancer (Kim and
Sharpless, 2012; Le Magnen et al., 2016). There are, however, some
fundamental differences between rodents and humans in responses to
drugs, including species differences in pathways of drugmetabolism and
disposition that can, at least in part, explain why preclinical studies
frequently do not extrapolate to the clinic.
Four cytochrome P450 gene subfamilies—Cyp1a, Cyp2c, Cyp2d
and Cyp3a—are predominantly involved in phase 1 drug metabolism
in man (Rendic and Guengerich, 2015). In mice these comprise
34 P450s, whereas only five enzymes are responsible for the metabolism
of the majority of drugs used clinically in man. In addition, the
expression levels of many of these enzymes (which determine levels
and variability in drug exposure) are controlled by two transcription
factors, the constitutive androstane receptor (CAR) and the pregnane X
receptor (PXR). These nuclear receptors also exhibit marked species
differences in their activation by drugs and exogenous chemicals
(Mackowiak et al., 2018).
To circumvent the species differences in drug disposition and to create
models that more closely reflect human drug response, a number of
humanized mouse lines have been reported. In some cases these have
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also involved humanization for both CAR and PXR (Gong et al., 2005;
Dragin et al., 2007; Gonzalez, 2007; Ross et al., 2010; Scheer et al.,
2010, 2012a,b, 2015; Scheer and Wolf, 2014; Durmus et al., 2015; Liu
et al., 2015). These models have usually also involved the deletion of
genes in the orthologous murine gene family. However, problems in the
utility of these models have arisen in that cytochrome P450s in the
remaining murine gene families can catalyze the reactions being studied.
Indeed, compensatory changes resulting in the induced expression of
murine P450s have been observed (van Waterschoot et al., 2008). In
addition to this confounding factor, mice carrying individual human-
izations are expensive to maintain, and any individual line would not
allow for evaluation of the complexities of the possible interactions
between multiple human P450s.
To create a model system that accurately reflects human pathways of
phase 1 drug metabolism, we deleted 33 murine P450s of the Cyp1a,
Cyp2c, Cyp2d, and Cyp3a gene subfamilies and replaced them with the
major human drug metabolizing P450s CYP1A1, CYP1A2, CYP2C9,
CYP2D6, CYP3A4, and CYP3A7, together with the transcription
factors CAR and PXR. Through the use of this model the role of the
P450 system in the disposition of a particular compound can be esti-
mated, and we demonstrate how such models can be used to accurately
predict human drug exposure and pharmacokinetics. We discuss their
significant potential to improve the drug development paradigm and the
design of combination clinical trials. We also discuss how the models
can be applied, in an era of polypharmacy, to reduce the risks of serious
drug-drug interactions and to personalize the treatment of disease.
Materials and Methods
All chemicals were purchased from Sigma Aldrich (Poole, Dorset, UK) unless
otherwise specified and were of the highest grade available.
Animals
The animals used in this work were originally generated in a collaboration
between CXRBiosciences (now Concept Life Sciences) and Taconic Biosciences
in a project funded by the Scottish Government through the ITI program (principal
investigators C.R.W. and N.S.). The mouse lines described in this manuscript
were developed under a material transfer agreement between Taconic and the
University of Dundee.
Taconic delivered cohorts of animals to University of Dundee and granted
University of Dundee rights to breed, crossbreed, and maintain colonies of the
animals at the Medical School Resource Unit, University of Dundee. All animals
were supplied from the Medical School Resource Unit, University of Dundee, on
a C57BL/NTac background. Mice were maintained in Tecniplast Sealsave micro-
isolator cages containing Eco-Pure chip7D (Datesand Group, Manchester, UK)
for bedding with ad libitum access to food (RM1; Special Diet Services,
Stepfield, Essex, UK) and water, and a 12-hour light-dark environment. Temper-
ature and relative humidity were maintained between 20C and 24C, and 45% and
65%, respectively.
All animal work described was approved by the Welfare and Ethical treatment
of Animals Committee of the University of Dundee. Those carrying out this work
did so with Personal and Project Licenses granted by the UK Home Office under
the Animals (Scientific Procedures) Act 1986, as amended by EU Directive
2010/63/EU.Animals were inspected regularly by staff trained and experienced in
small animal husbandry, with 24-hour access to veterinary advice.
At the end of studies, all animals were sacrificed according to Schedule 1 of the
Animals (Scientific Procedures) Act 1986, by exposure to a rising concentration
of CO2 and death confirmed by exsanguination.
Data in this paper was obtained using male and female mice at the ages
specified in this section and elsewhere. Mice were age-matched to within 1 month
of each other, unless otherwise stated. Animals were randomly assigned to control
or treatment groups; analysts were not blinded to the identity of biologic samples.
Animal numbers were guided by power calculations (G*Power; www.gpower.
hhu.de), pilot experiments, and previous experience, and experimental design
was undertaken in line the 3Rs principles of replacement, reduction, and refine-
ment (www.nc3rs.org.uk).
The 8HUM mouse line was generated by crossing a previously characterized
multiple humanized model (Scheer et al., 2015) in which the Cyp2c (except
Cyp2c44),Cyp2d orCyp3amurine gene clusters and the transcription factorsCar
and Pxr were deleted, and replaced with the corresponding human genes
(CYP2C9, CYP2D6, CYP3A4, CYP3A7, CAR, PXR) [Cyp2ctm1897(albCYP2C9)Arte
(Scheer et al., 2012a); Cyp2dtm1836(CYP2D6*2)Arte (Scheer et al., 2012b);
Cyp3atm1109(CYP3A4/3A7)Arte-Cyp3a13tm1728Arte (Hasegawa et al., 2011);
Nr1i2tm1198(NR1I2)Arte (Ross et al., 2010); Nr1i3tm1089(NR1I3)Arte (Scheer et al.,
2010)] with a line in which Cyp1a1 and Cyp1a2 were deleted and replaced
with CYP1A1 and CYP1A2 (Cyp1a1tm2025(CYP1A1)Arte-Cyp1a2tm2024(CYP1A2)Arte)
(Kapelyukh et al., manuscript in preparation). A total of 35 murine genes were
replaced by eight human genes. Expression of human P450 genes was from the
human promotor, except forCYP2C9, whichwas driven by the albumin promotor,
and CYP1A1 and CYP1A2, which were driven by the murine Cyp1a1 and
Cyp1a2 promoters, respectively. CAR and PXR were expressed off the
corresponding murine promoters.
A model, CypC4KO, in which the Cyp1a, Cyp2c, Cyp2d, and Cyp3a gene
clusters were deleted (34 genes, includingCyp2c44) but murineCar and Pxrwere
retained, was also generated.
8HUM mice were maintained by crossing males homozygous for the gene
deletions and humanization described above with females heterozygous for the
Cyp2c gene cluster deletion/CYP2C9 humanization and retention of one allele of
the murine Cyp2c gene cluster (see below). Homozygous CypC4KO mice were
bred using a similar strategy.
Animal Treatments
Rifampicin.Micewere dosed intraperitoneallywith rifampicin (RIF; 10mg/kg
in vehicle) or vehicle (corn oil) daily for 3 days. On day 4, mice were sacrificed for
tissue collection.
2,3,7,8-Tetrachlorodibenzodioxin.Mice were given a single dose of 2,3,7,8-
tetrachlorodibenzodioxin (TCDD) (10 mg/kg) or vehicle (corn oil) by intraper-
itoneal injection, and samples of liver and small intestine were collected 48 hours
after the dosing.
St. John’s Wort. Mice were dosed with either St. John’s Wort (SJW) tablets
(Kira LowMood relief St. John’s Wort extract 450 mg; batch XD092056,
marketed in Germany as Jarsin; Klosterfrau Healthcare Group) or the active
ingredient hyperforin (Phytoplan Diehm and Neuberger GmbH, Heidelberg,
Germany).
An extract was made from the SJW tablets as follows: Tablets were crushed
usingmortar and pestle, mixed with 100% ethanol (1 ml per tablet), and placed on
a rotator mixer (SB3; Stuart Scientific, UK) for 1 hour in a dark room. Themixture
was centrifuged (16.1 krcf; 4C; 10 minutes), and the supernatants were removed
and pooled together in an amber Eppendorf tube. Just before administration the
extract was mixed with PEG 400 (final ethanol concentration;13.9%) and given
to mice at a volume of 5 ml/kg by oral gavage. The SJW extract dose was
312 mg/kg assuming 100% extraction efficiency by ethanol. Considering that
measured hyperforin content in Jarsin (Kira) SJW extract is in a range of 2.22%–
3.07% (Wurglics et al., 2001), the SJW extract dose we used in the study translates
to 6.9–9.6 mg/kg of hyperforin. The dose of 18 mg/kg of hyperforin/adhyperforin
dicycloammonium salt translates to 13.4 mg/kg of hyperforin/adhyperforin and to
10.7 mg/kg of hyperforin (the hyperforin content was ;80% of total hyper-
forin/adhyperforin according to the reagent batch high-performance liquid
chromatography analysis provided by the reagent supplier).
In Vivo Pharmacokinetic Experiments
Pharmacokinetics of Caffeine, Debrisoquine, Midazolam, and Tolbuta-
mide Administered as a Cassette Dose. Female 8HUM mice received either
two daily intraperitoneal doses of RIF (n = 4; 20–26 weeks) or vehicle (corn
oil; n = 4; 25–29 weeks). On day three all animals were administered
caffeine (5 mg/kg), debrisoquine (5 mg/kg), tolbutamide (5 mg/kg), and
midazolam (3 mg/kg) as a cassette dose by oral gavage. Blood samples
(10 ml) were collected at the indicated time points after dosing, mixed
immediately with 10 ml of heparin (15 IU/ml), snap frozen in liquid nitrogen,
and stored at approximately 270C prior to analysis (see Supplemental Data
for details).
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Pharmacokinetics of Caffeine, Debrisoquine, and Midazolam Administered
as a Cassette Dose to St. John’s Wort Pretreated Mice: Effect of Quinidine
and Ketoconazole. Two groups of female 8HUM mice received two daily oral
doses of SJW (n = 6; 17–18weeks) or vehicle (n = 6; 15–17weeks; 13.9% ethanol
in PEG400). On day three, one of the SJW-treated groups (n = 3) was administered
ketoconazole (35 mg/kg) and quinidine (30 mg/kg) by oral gavage and the
other two groups received vehicle (12% ethanol in PEG400) 30 minutes before
administration of caffeine (5 mg/kg), debrisoquine (5 mg/kg), and midazolam
(3 mg/kg) as a cassette dose by oral gavage. Blood sampling and analysis was
carried out as described above and in Supplemental Data.
Effect of Dabrafenib Pretreatment on Midazolam Pharmacokinetics
Female 8HUM mice received either two daily oral doses of dabrafenib (n = 3;
15 weeks; 10 mg/kg) or vehicle (n = 3; 16 weeks; 0.5% hydroxypropylmethyl-
cellulose, 0.2% Tween 80). On day 3 both groups were administered midazolam
(3 mg/kg) by oral gavage. Whole blood collection and sample preparation were
performed as described above, and analytical details are described in Supple-
mental Data. A third group of female 8HUMmice (n = 3; 17–22 weeks) received
two daily doses of dabrafenib (10mg/kg) by oral gavage andwere culled for tissue
collection on day 3 to allow determination of the effects of dabrafenib on P450
expression at the start of the pharmacokinetic (PK) study.
Effect of Sulfaphenazole on Pharmacokinetics of S-Acenocoumarol
Mice were administered two daily doses of SJW before receiving a single oral
dose of S-acenocoumarol (1 mg/kg). S-acenocoumarol was dissolved in dimethyl
sulfoxide (1 mg/ml) and diluted 10-fold in 100 mM potassium phosphate buffer
(pH8) or in a solution of sulfaphenazole (9.78 mg/ml) in the same buffer.
Compounds were administered to mice at a volume of 10 ml/kg. Blood collection
and sample preparation was performed as described above and analytical details
are provided in Supplemental Data.
Effect of SJW and Hyperforin on Dabrafenib Pharmacokinetics
Mice were administered two daily doses of SJW, hyperforin/adhyperforin
dicycloammonium salt (18 mg/kg), or vehicle (13.9 ethanol in PEG400) by oral
gavage. On day 3 all animals were administered dabrafenib (10 mg/kg). Whole
blood collection and sample preparation were performed as described above and
analytical details are described in Supplemental Data.
Pharmacokinetic Data Analysis
Pharmacokinetic parameters were calculated by Phoenix WinNonlin version
8.0.0.3176 (Certara, Princeton, NJ).
Tissue Harvesting and Processing for Immunohistochemistry
Liver and duodenum were removed postmortem, rinsed in ice-cold sterile
PBS, and fixed in Gurr buffer overnight before transfer into 70% (v/v) ethanol.
The following day organs were dehydrated and embedded in paraffin and
subsequently sectioned at a 5-mm thickness using a Shandon Finesse 325 micro-
tome. Sections were deparaffinized in xylene and rehydrated through a graded
series of 100% to 50% (v/v) ethanol solutions, followed by immersion in distilled
water. Antigen retrieval was carried out by immersion of slides in 10 mM sodium
citrate buffer, pH 6, and heating in a microwave for 25 minutes on high power,
before being allowed to cool to room temperature. After a washing in water,
treatment for10minuteswith 0.3% hydrogen peroxide, andwashing in phosphate-
buffered saline (PBS) and PBS-Tween (0.05% Tween-20, v/v), slides were dried
and a hydrophobic pen was used to draw round the section. Slides were then
blocked [Dako Endogenous enzyme block, followed by a nonspecific block using
normal goat serum (5% v/v) in PBS-Tween] before a washing in PBS-Tween and
incubation overnight at 4C with primary antibody [anti-rat CYP3A1 (Forrester
et al., 1992)] 1:100 dilution in 5% normal goat serum in PBS-Tween. After a
washing in PBS-Tween, slides were dried and incubated with secondary antibody
(Dako anti-rabbit HRP) for 30 minutes at room temperature. Slides were washed
in PBS-Tween and immunoreactivity visualized using Dako DAB+ chromogen
kit according to manufacturer’s instructions. After a washing in PBS and water,
slides were counterstained with hematoxylin before dehydration in a series of
increasing-alcohol steps, ending in xylene. Slides were dried for 5–10 minutes
before coverslips were mounted in DPX mountant.
Sections were examined using a Zeiss Axio Scope.A1 Polarized Light
Microscope. Images of tissue sections were taken using a Carl Zeiss Axiocam
color processed through Axiovision v4.8.2 imaging software.
Preparation of Microsomes
Fresh liver samples from wild-type or humanized mice were homogenized
in ice-cold SET buffer (0.25 M sucrose, 5 mM EDTA, and 20 mM Tris-HCL,
pH 7.4) to make a 10% (w/v) homogenate solution (9 ml SET buffer/1 g liver)
using Polytron PT-MR-2100 homogenizer. Liver homogenates were centrifuged
at 2000 rpm (Sorvall RTH-250 rotor) for 10 minutes at 4C. The supernatant was
then spun at 12,000 rpm (Sorvall SS-34 rotor) for 20minutes at 4C. The resulting
supernatantwas centrifuged at 29,130 rpm (Sorvall TFT-45.6 rotor) for 90minutes
at 4C, and the microsomal pellets were resuspended in ice-cold SET buffer and
stored at 270C.
Frozen individual duodenum samples were homogenized in SET buffer
containing protease cocktail inhibitor (Roche) and phenylmethylsulfonyl fluoride
(PMSF; 1 mM) using a Polytron homogenizer. Tissue homogenates were
subjected to subcellular fractionation by differential centrifugation like that de-
scribed for the preparation of liver microsomes. Microsomal fractions were stored
at approximately 270C prior to analysis. The protein concentration in the
microsomal fractions was determined using a modification of the method of
Lowry (Lowry et al., 1951) and bovine serum albumin standards, and total
microsomal P450 was measured by difference spectra of reduced heme iron
complex with carbon monoxide (Omura and Sato, 1964).
Cytochrome c Reductase Activity
A mixture of cytochrome c from bovine heart (40 mM) and mouse liver
microsomes (;7.6 mg/ml) in 0.3 M potassium phosphate buffer (pH 7.7) was
incubated at 37C for at least 2 minutes before the reaction was started by addition
of NADPH (0.1 mM final concentration). The absorbance at 550 nmwas recorded
and the reaction rate calculated from the linear region of the absorbance time
course. The extinction coefficient of 0.0211 mM21cm21 was used (van Gelder
and Slater, 1962) to calculate concentration of the reduced cytochrome c.
Dextromethorphan O-Demethylation
A mixture of dextromethorphan (10 mM) and 8HUM liver microsomes
(;0.25 mg/ml protein) in phosphate buffer (100 mM KH2PO4 pH7.4, 3.3 mM
MgCl2) was incubated for 5 minutes at 37C prior to the addition of NADPH
(final concentrations 1.3 mM). After 5 minutes, the reaction was stopped by
combining 100 ml of the reaction mixture with 120 ml of 0.2 M hydrochloric
acid containing dextrorphan-d3 (92 ng/ml) as an internal standard. The mixture
was placed on ice for at least 20 minutes, centrifuged at 16.1 krcf for 15 minutes
at +4C, and 100 ml of the supernatant transferred to a 96-well plate for
analysis. The concentrations of dextromethorphan were measured by liquid
chromatography–tandem mass spectrometry (LC-MS/MS). Chromatographic
separation was performed on a Kinetex Biphenyl 100 Å column (5 mm; 5.0 
2.1 mm) (Phenomenex, Macclesfield, UK) using an injection volume of 10ml and a
run time of 5 minutes. The detector used was a Micromass Quattro Micro mass
spectrometer (Waters Corporation, Milford, MA) run in electrospray positive ion
mode. The multiple reaction monitoring parameters for dextrorphan and
dextrorphan-d3 were 258.16 and 261.24 (precursor ions) and 157.04 (one product
ion for both compounds), respectively.
In Vitro Kinetic Parameter Determination
All in vitro analyses were carried out in 100 mM potassium phosphate buffer,
pH 7.4, containing 3.3 mM MgCl2, with agitation at 400 rpm at 37C on a
thermoshaker. All samples were handled in amber tubes under conditions of
subdued light for the duration of the procedure. Incubations were initiated by the
addition of NADPH to a final concentration of 1.3 mM and were terminated by
transferring an aliquot of the reaction mixture, typically 50 ml, to one volume of
ice-cold acetonitrile containing 400 ng/ml of triazolam as internal standard,
followed by vortexing (5 seconds), and incubation on ice. The samples were then
centrifuged at 3000g for 55 minutes at 4C and an aliquot of the supernatant
fraction was analyzed by LC-MS/MS. Assays to determine the apparent kinetic
parameters of 1-hydroxyl midazolam (CYP3A4), 4-hydroxyl tolbutamide (CYP2C9),
and 4-hydroxyl debrisoquine (CYP2D6) formation in pooled rifampicin-treated
Humanized Mice for Predicting Drug Response 603
 at A
SPET Journals on M
ay 28, 2019
dm
d.aspetjournals.org
D
ow
nloaded from
 
male and female 8HUM mice (8HUM) or pooled human liver microsomes
(HLM) were performed in triplicate under conditions of linearity for time (2, 40,
and 40 minutes for 1-hydroxyl midazolam, 4-hydroxyl tolbutamide, and
4-hydroxyl debrisoquine, respectively) and microsome protein (0.05, 0.1, and
0.1 mg/ml for 1-hydroxyl midazolam, 4-hydroxyl tolbutamide and 4-hydroxyl
debrisoquine, respectively).
Calibration curves were constructed with authentic metabolite standards and
linear regression analysis used to calculate the amount of metabolite formed in
each test sample. Apparent Km and Vmax values were estimated by nonlinear
regression analysis (GraphPad Prism version 6.05) of the substrate concentra-
tion [S]-enzyme activity [V], fitting data to a Michaelis-Menten model. The
7-ethoxyresorufin O-deethylation assay was carried out as detailed below.
7-Methoxyresorufin O-Demethylation and 7-Ethoxyresorufin O-Deethylation
Amixture of either 7-methoxyresorufin or 7-ethoxyresorufin (1 mM) and 8HUM
liver microsomes or HLM (;0.38 mg protein/ml) in 100 mM potassium phosphate
buffer (pH 7.4) supplemented with MgCl2 (3.3 mM) was incubated at 37C for
5minutes before the addition ofNADPH (final concentration 1.2mM).Generation of
the fluorescent product was registered in a kinetic mode using Fluoroscan Ascent
FL (Labsystems; excitation filter 530 nm; emission filter 585 nm). Slopes of the
linear part of the kinetic curves were calculated using Ascent Software Version
2.4.1 (Labsystems). For each reaction two controls, with and without reaction
product resorufin (40 pmol) were run. Fluorescence was measured from both
control wells and the difference in fluorescence intensity between wells with and
without resorufin was used for the conversion of the relative fluorescence units to
the picomoles of the reaction product.
Dibenzylfluorescein O-Debenzylation
The O-debenzylation of dibenzylfluorescein (DBF) was measured as de-
scribed above for the 7-methoxyresorufin O-demethylation assay, with the
following modifications: the DBF concentration was 2 mM; the excitation filter
was 485 nm; the emission filter was 530 nm; 20 pmol of the fluorescein was added
to the control wells.
7-Benzyloxyquinoline O-Debenzylation
The 7-benzyloxyquinoline debenzylation was measured as described above
for the 7-methoxyresorufin O-demethylation assay, with the following modifica-
tions: The 7-benzyloxyquinoline concentration was 100 mM; the excitation
filter was 405 nm; the emission filter was 530 nm; 40 pmol of the metabolite
7-hydroxyquinidine was added to the control wells.
Enzyme Inhibition Assay
Substrate cocktail containing caffeine (220 mM), debrisoquine (67 mM),
tolbutamide(2 mM), and midazolam (3 mM) were incubated using 8HUM or
HLM (UltraPoolHLM150, Mixed Gender, product no. 452117; Corning)
(0.25 mg/ml) in the presence or absence of the isozyme-specific inhibitors
fluconazole (300 mM), sulfaphenazole (3 mM), quinidine (3 mM), paroxetine
(10 mM), or ketoconazole (1 mM). After a 5-minute preincubation at 37C,
reactions were initiated by addition of NADPH (1.3 mM). In the case of
furafylline (3mM), enoxacin (200mM), and paroxetine (10mM) the inhibitor was
preincubated with NADPH (1.3 mM) in 100 mM potassium phosphate buffer
(pH 7.4) and 3.3 mM MgCl2 for 30 minutes at 37C prior to the addition of the
substrate cocktail. After a 10-minute incubation (20 minutes for furafylline and
enoxacin) the reaction mixture was quenched with 100 ml of cold acetonitrile
containing 0.3% formic acid and 400 ng/ml of triazolam as internal standard. The
samples were then centrifuged at 3000g for 55 minutes at 4C, and an aliquot of
the supernatant fraction was analyzed by LC-MS/MS. All experiments were
performed at least in triplicate.
Microsomal Stability of S-Acenocoumarol
A mixture of acenocoumarol (1 mM) and liver microsomes (2 mg protein/ml)
from wild-type (WT), hepatic P450 reductase–null (HRN), Cyp2c KO,
Cyp2c/Cyp2d/Cyp3a KO, or CYP2C9 humanized mice in phosphate buffer
(100 mM KH2PO4 pH7.4, 3.3 mM MgCl2) was incubated in a water bath for
5 minutes at 37C prior to the start of the reaction by addition of NADPH
regenerating system (final concentrations: 1.3 mM NADPH, 4 mM glucose-6-
phosphate, and 2 IU/ml glucose-6-phosphate dehydrogenase). The reaction
mixture aliquots were taken at specified time points and mixed with an equal
volume of acetonitrile containing warfarin (50 ng/ml) as an internal standard. The
mixture was placed on ice for at least 20 minutes, centrifuged at 16.1 krcf for
15 minutes at +4C, and 100 ml of the supernatant was transferred to a 96-well
plate for analysis. The concentrations of S-acenocoumarol were measured by
LC-MS/MS. Chromatographic separation was performed on a KinetexC18 100Å
column (2.6 mm; 5.0  2.1 mm) (Phenomenex) using an injection volume of
10 ml and a run time of 7 minutes. The detector used was a Micromass Quattro
Micro mass spectrometer (Waters Corporation) run in electrospray positive ion
mode. The multiple reaction monitoring parameters for S-acenocoumarol and
warfarin were 354.06 and 309.1 (parent ions) and 163.08 and 251.15 (collision
ions), respectively.
Liquid Chromatography-Mass Spectrometry-Multiple Reaction
Monitoring Analysis
Drug analyses of the in vitro incubations and in vivo PK samples were carried
out by UPLC-MS/MS using a Waters Acquity UPLC (Micromass, Manchester,
UK) and Micromass Quattro Premier mass spectrometer (Micromass) with
electrospray detection. Chromatography was performed using a C18 column
(Kinetex 1.7 mm 100 A; 50  2.1 mm; Phenomenex) at a temperature of 45C
with mobile phases of 0.1% formic acid (A) and acetonitrile containing 0.1%
formic acid (B). A gradient at a flow rate of 0.5 ml/min was run over 3 minutes
as follows: 0–0.5 minutes: 95% A; 0.5–0.75 minutes: 95%–80% A; 0.75–
1.50 minutes 80% A, 1.50–2.00 minutes 80%–50% A, 2.00–2.50 minutes
50%–5% A, then returning to initial conditions for final 0.5 minutes. The cone
voltage and collision energy were optimized for each substrate and multiple
reaction monitoring data were acquired (Supplemental Table 2).
Results
The generation of the 8HUM and CypC4KO models together with
the initial characterization of the 8HUM model are presented in the
Supplemental Data. Total hepatic P450 in untreated 8HUM mice
(male: 220 6 29, female 165 6 11 pmol P450/mg protein) were lower
than those measured in wild-type animals (male 3196 42, female 3886
32 pmol P450/mg protein, P , 0.005 and P , 0.003, respectively,
Fig. 1A). Following treatment with the PXR activator rifampicin P450
levels increased to 353 6 70 (male) and 247 6 120 pmol (female)
P450/mg protein. The expression of individual hepatic P450 isozymes
following RIF treatment was remarkably similar to the mean levels
found in human liver (Fig. 1B). As the only human enzyme induced by
RIF was CYP3A4, the change in total P450 content could be ascribed
predominantly to the change in the level of this protein. Thus, of the total
P450, CYP3A4 was 38% and 33% for males and females, respectively.
This is very similar to the average level of this enzyme found in human
liver (Michaels and Wang, 2014). As in humans and consistent with our
previous findings (Hasegawa et al., 2011), CYP3A4 was expressed
constitutively in the duodenums of 8HUM mice and was slightly
induced on RIF treatment (Fig. 1B). CYP3A4 expression was also
detected at lower levels in the jejunum and in the ileum (Supplemental
Fig. 3). CYP2D6 was also expressed in this tissue at significant levels.
CYP3A4 was constitutively localized in a few cells around the central
vein in the liver. Following RIF treatment, the staining became more
intense and remained in this region, which is consistent with the
localization of CYP3A4 in human liver (Palmer et al., 1992). In the small
intestine, CYP3A4 was localized in the villi, the most intense staining
being observed in the duodenum (Fig. 1C), which is also consistent
with the localization of this enzyme in the human gastrointestinal tract
(Fritz et al., 2019).
In Vitro P450 Activity Measurements. The in vitro hepatic
activity of the human P450 enzymes expressed in the 8HUM model
was determined by measuring the metabolism of a series of drugs
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that are substrates for specific human P450 enzymes (Table 1).
Mice were pretreated with RIF to increase the expression of CYP3A4
(Fig. 1). The Km value obtained for each human P450 was not signif-
icantly different (F-test) from that measured in pooled HLM (Table 1),
inferring similar affinities in the 8HUM and HLM, allowing direct
extrapolation of drug-drug interaction data obtained in 8HUM mice to
man. The Vmax values, which are determined by the level of expression
of each individual isozyme, were also similar but in some cases higher
than the HLM values.
We then established the capacity of P450 isozyme inhibitors to
reduce the metabolism of these substrates and compared the level of
inhibition to that measured in a pooled human liver microsomal
preparation (Table 2). A close correlation was observed between
the level of inhibition measured with 8HUM samples and those with
HLM.Metabolism of CYP1A2, CYP2C9, andCYP3A4 isoform-specific
substrates in HLM and liver microsomes from 8HUMmice demonstrated
a similar degree of inhibition by the isoform-specific inhibitors furafyl-
line, enoxacin (CYP1A2), sulfaphenazole (CYP2C9), and ketoconazole
Fig. 1. Expression of human cytochrome P450s in 8HUM mice. (A) Total hepatic P450 was determined from the carbon monoxide difference spectra (as described in
Materials and Methods) in untreated male and female wild-type mice (WT; n = 3–8), and male and female 8HUM mice (n = 3) vehicle (white bars) and rifampicin-treated
daily for 3 days (black bars; 10 mg/kg, i.p.). Data shown are mean 6 S.D.; t test (two-tailed P values), statistically significant **P , 0.01; ***P , 0.001. (B) Immunoblot
analysis of human P450 expression in liver and duodenum. Western blots were carried out on pooled microsomal fractions (n = 3) of liver and duodenum, as described in
Materials and Methods, using antibodies specific for the human P450s shown. Std, His-tagged P450 standard; TCDD, 2,3,7,8-tetrachlordibenzodioxin-treated; Veh, vehicle-
treated. (C) Immunohistochemical localization of CYP3A4 in liver and duodenum of vehicle- and rifampicin-treated 8HUM mice. Liver and duodenum from adult female
8HUM mice—vehicle- or rifampicin-treated for 3 days at 10 mg/kg i.p.—were processed for immunohistochemical staining as described in Materials and Methods.
Photomicrographs shown are representative of n = 3.
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(CYP3A4). Fluconazole inhibited metabolism of tolbutamide and
midazolam to the same extent in both species, consistent with dual
P450 isoform specificity of this inhibitor (Brown et al., 2006). Although
the CYP2D6-specific reaction of debrisoquine 4-hydroxylation was
inhibited in both HLM and microsomes from 8HUM mice by quinidine
and paroxetine, the extent of the inhibition demonstrated some
species differences (2- and 4-fold, respectively).
Effect of Rifampicin Treatment on Drug Pharmacokinetics. The
P450 enzymes provide an adaptive response to chemical challenge
where the level of expression of individual enzymes is regulated by
drugs, herbal medicines, industrial chemicals, and environmental agents
in a manner that increases the rate of drug disposition. Pathways leading
to the induction of the P450s, for example through CAR and PXR, are
complex particularly when multiple drug combinations are being used.
Currently available in vivo and in vitro models only give limited
information about such interactions. P450 induction can result in loss of
drug efficacy both for the primary target and the other drugs given
concomitantly. Such effects can also increase the rate of formation of
toxic metabolites.
We carried out an in vivo study to investigate the effects of RIF
pretreatment on the pharmacokinetics of the probe drug substrates
(Fig. 2). In the case of the CYP3A4 substratemidazolam, pretreatment of
mice with RIFmarkedly altered the pharmacokinetics of this compound,
reducing drug exposure from an AUCall of 860.36 138.1 hour*ng/ml to
68.82 6 21.14 hour*ng/ml (n = 4) vs. P = 0.001). Unexpectedly, RIF
treatment also affected the clearance of compounds for which CYP3A4
is not the primary route of elimination, with the exposure of both
caffeine (CYP1A2; AUCall 5142 6 685.1 hour*ng/ml vs. 14,574 6
4253 hour*ng/ml; P = 0.05) and tolbutamide (CYP2C9; AUCall
38,476 6 10,218 hour*ng/ml vs. 197,956 6 4157 hour*ng/ml;
P # 0.001) also being decreased. In contrast, debrisoquine exposure
(CYP2D6;AUCall 18606426.5 hour*ng/ml vs. 1331653.5 hour*ng/ml;
n/s) was increased in response to RIF, possibly owing to the suppression
of CYP2D6 by RIF; however, this difference was not significant.
To establish whether the reductions in drug exposure following
RIF treatment were the result of changes in P450 enzyme activity,
we measured in vitro rates of metabolism with probe substrates. The
hydroxylation of 7-BQ, a CYP3A4 substrate, was increased approxi-
mately 2-fold as a consequence of rifampicin treatment (42186 550 vs.
1889 6 536 pmol/min per milligram; P = 0.03). There was no
difference between the samples in metabolism of the CYP1A2 substrate
7-methoxyresorufin (42.84 6 9.93 vs. 47.45 6 3.65 pmol/min per
milligram; not statistically significant). Incubations in the presence of the
CYP1A2 inhibitora-naphthoflavone (3.33mM) inhibited this activity in
both sets of samples to a similar extent, 75% and 93%, respectively. The
observed increase in caffeine clearance in vivo, was therefore not the
result of changes in CYP1A2 activity. Tolbutamide 4-hydroxylation
in vitro was also similar between rifampicin-treated groups and controls
(71.22 6 10.23 vs. 52.256 7.17 pmol/min per milligram; n/s), and the
CYP2C9 inhibitor sulfaphenazole (50 mM) almost completely inhibited
this activity in both groups (remaining activity 11.436 9.38 vs. 2.016
0.33 pmol/min per milligram; n/s). The reason for the unexpected
changes in pharmacokinetics for caffeine and tolbutamide in this
experiment are therefore intriguing and could be attributable to changes
in phase 2 enzymes or to the expression of drug transporters.
We then investigated the effects of PXR activation on the pharma-
cokinetics of the anticancer drug dabrafenib, used as the standard of care
in the UK for the treatment of BRAFmutant metastatic melanoma (Long
et al., 2016). Female 8HUMmice were treated with vehicle (corn oil) or
rifampicin (10 mg/kg, i.p) on three consecutive days prior to adminis-
tration of dabrafenib [10 mg/kg, by mouth (PO)]. One group also
received the CYP3A4 inhibitor ketoconazole (20 mg/kg, PO) 30 min
before the administration of dabrafenib. Pretreatment with RIFmarkedly
reduced the AUC of dabrafenib to approximately 28% of that in vehicle-
treated animals; corresponding reductions in Cmax and half-life were also
observed (Fig. 3). Prior administration of ketoconazole significantly
increased dabrafenib exposure, approximately doubling both the Cmax
and AUC (Fig. 3).
Detection of Human-Specific Metabolites in the 8HUM Mouse.
Humans and rodents metabolize drugs down different pathways and also
generate different metabolites both in their site of oxidation as well as in
different metabolite ratios when multiple sites of oxidation are involved.
TABLE 1
Kinetic parameters for probe compound metabolism in 8HUM mice
Hepatic microsomal fractions from pooled rifampicin-treated male and female 8HUM mice or pooled human liver microsomes were used. Data presented as mean 6 S.D. on biologic triplicate
samples. F-test comparing 8HUM and HLM data for each substrate showed no significant difference. Enzyme activities were determined as described in Materials and Methods.
Substrate
CYP1A2 7-Ethoxyresorufin CYP2C9 Tolbutamide CYP2D6 Debrisoquine CYP3A4 Midazolam
HLM 8HUM HLM 8HUM HLM 8HUM HLM 8HUM
Km (mM) 0.22 6 0.04 0.35 6 0.05 73 6 16 137 6 36 25 6 7 57 6 8 0.73 6 0.20 1.2 6 0.3
Vmax (pmol/min per milligram protein) 12.3 6 0.5 20.7 6 0.9 2.5 6 0.1 2.7 6 0.2 25 6 2 98 6 6 1500 6 100 5100 6 500
TABLE 2
In vitro inhibition of hepatic CYP1A2, CYP2C9, CYP2D6, and CYP3A4 in 8HUM and HLM microsomal fractions
Data are presented as percent of activity measured in the absence of inhibitor. Values are mean 6 S.D. from a minimum of 3 determinations. Other experimental details are given in Materials and
Methods.
Inhibitors
Caffeine (Paraxanthine) Debrisoquine (4-OH Debrisoquine) Tolbutamide (OH-Tolbutamide) Midazolam (1-OH-Midazolam)
HLM 8HUM HLM 8HUM HLM 8HUM HLM 8HUM
Furafylline (CYP1A2) 53 6 6* 56 6 13* 65 6 9 91 6 13 103 6 25 63 6 19 95 6 8 92 6 7
Enoxacin (CYP1A2) 58 6 15* 52 6 8* 82 6 29 89 6 13 72 6 27 73 6 13 99 6 13 90 6 4
Fluconazole (CYP2C9/CYP3A4) 114 6 37 100 6 31 96 6 9 88 6 19 35 6 21* 41 6 33* 29 6 4*** 42 6 5***
Sulfaphenazole (CYP2C9) 78 6 26 67 6 15 79 6 25 88 6 36 14 6 4** 28 6 15** 107 6 21 125 6 41
Quinidine (CYP2D6) 105 6 28 74 6 7 22 6 5* 43 6 5* 75 6 17 132 6 29 83 6 9 97 6 18
Paroxetine (CYP2D6) 66 6 26 95 6 22 52 6 11* 13 6 5** 113 6 50 117 6 34 91 6 8 109 6 17
Ketoconazole (CYP3A4) 135 6 45 85 6 34 142 6 42 152 6 11 154 6 66 92 6 11 6 6 2*** 11 6 2***
*P , 0.05, **P , 0.01, ***P , 0.001, compared with no inhibitor; unpaired t test, two-tailed P values;
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The in vivo significance of this species difference can be of particular
importance when the metabolites are either pharmacologically active,
i.e., in drug efficacy, or toxic. To demonstrate the potential utility of the
8HUM mouse to recreate the bona fide pathways of human drug
disposition we studied the metabolism of the epidermal growth factor
receptor inhibitor osimertinib. Mice were pretreated with either RIF or a
combination of RIF and b-naphthoflavone (BNF), an aryl hydrocarbon
receptor agonist that induces P450s in the CYP1A gene family. The half-
life of osimertinib in the 8HUM was greater than 20 hours versus
3.5 hours in WT mice [(Cross et al., 2014); Fig. 4]. The clearance of
osimertinib was increased in 8HUMmice treated with RIF, and a further
increase occurred when mice were also pretreated with BNF (Fig. 4).
These data, consistent with our previous report using a simpler humanized
model (MacLeod et al., 2018), suggest that members of the CYP1A gene
family are involved in osimertinib disposition. The major human
metabolites of osimertinib were detected in 8HUM mice (Fig. 4C).
The above data together with our previous report demonstrate major
species differences in the disposition of this compound both in the levels
of drug exposure, in PK parameters, in the ratio of metabolites produced,
as well as the P450 gene families involved (see Discussion).
Effects of Alternative PXR Activators on CYP3A4 Levels in the
8HUMMouse. RIF, although a potent human PXR activator, was toxic
in the 8HUMmodel. On RIF treatment, liver enlargement and elevations
in circulating liver enzymes were observed. On histopathological
examination there was evidence of hepatic endothelial cell proliferation
and increased numbers of Kupffer cells, suggesting possible hepatocyte
damage. Oval cell and bile duct proliferation were also in evidence.
We therefore sought to identify a specific, clinically relevant PXR
agonist that was nontoxic. A number of PXR activators were tested in the
simpler CAR/PXR/CYP3A4 model (Hasegawa et al., 2011; MacLeod
et al., 2015, 2018). These were: the herbal medicine St. John’s Wort
(SJW), the anti-HIV drug efavirenz (EFV), the anticonvulsant pheno-
barbital (PB), and the glucocorticoid dexamethasone (DEX). With the
exception of DEX, all the compounds tested were effective inducers of
CYP3A4 (Supplemental Fig. 4). Of particular note was SJW, which
specifically induced CYP3A4 in the absence of toxicity and with only
minimal induction of Cyp2b10 expression. Subsequent studies were
therefore undertaken using SJW to induce CYP3A4 expression in
8HUM mice.
To test the effects of SJW as an inducing agent in vivo, animals
received two daily doses of SJW, followed by a single cassette dose
of midazolam, debrisoquine and caffeine. Two groups of mice also
received a single dose of ketoconazole and quinidine 30 minutes
prior to cassette administration. Treatment with SJW caused a 12-fold
decrease in midazolam AUC, and additional administration of ketoco-
nazole resulted in a 4.7-fold increase in exposure to the compound
(Fig. 5; Supplemental Table 1). These data are consistent with induction
of hepatic CYP3A4 and subsequent inhibition of the enzyme by the
isoform-specific inhibitor. Treatment with SJW also resulted in a 2-fold
increase in debrisoquine AUC, possibly owing to downregulation of
constitutive CYP2D6 expression by PXR ligands in females (Fig. 1B)
(Scheer et al., 2015). The CYP2D6-specific inhibitor quinidine caused
an 8.1-fold increase in the AUC of debrisoquine in the SJW-treated
group. Neither SJW nor ketoconazole or quinidine significantly affected
the pharmacokinetics of the CYP1A2-specific substrate caffeine,
although an approximately 50% reduction in AUC was observed on
SJW treatment. The above data are similar to those obtained using RIF.
In view of the long half-life of tolbutamide, both in mice and humans,
together with solubility issues and the indications that in addition to
CYP2C9 other non-P450 pathways are involved in its disposition, we
tested an alternative CYP2C9 probe drug, S-acenocoumarol (Ufer,
2005). S-acenocoumarol has several advantages over tolbutamide as it
has a higher CYP2C9 specificity [fraction metabolized by CYP2C9 is
0.94 (Thijssen et al., 2001), comparedwith 0.85 for tolbutamide (Perkins
et al., 2018)]. S-acenocoumarol is cleared rapidly in man (Thijssen et al.,
2001), which is a distinct advantage in drug-drug interaction studies,
Fig. 2. Effect of rifampicin on the pharmacokinetics of human P450 substrates. Adult female 8HUM mice (n = 3 or 4) were treated intraperitoneally with either vehicle
(corn-oil; open circles) or rifampicin (closed circles) at 10 mg/kg, daily for 2 days, and on day 3 were administered by oral gavage a cassette comprising midazolam, caffeine,
tolbutamide, and debrisoquine, and PK profiling was carried out as described in Materials and Methods. Data shown are mean 6 S.D.
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where drug elimination is slowed down by the inhibitor and for accurate
description of the terminal phase of the PK curve drug sampling is
needed over a prolonged period. In addition, S-acenocoumarol is a rare
example of a cytochrome P450 substrate that is resistant to metabolism
by other murine NADPH-dependent enzymes. S-acenocoumarol me-
tabolism inmicrosomes fromwild-type, Cyp2cKO, Cyp2c/2d/3a KO, or
hepatic P450 reductase–null (Henderson et al., 2003) mice was practi-
cally indistinguishable from that in the no cofactor control, whereas
S-acenocoumarol was rapidly metabolized in liver microsomes from
CYP2C9 humanized mice (Fig. 6A). In an in vivo drug-drug interaction
study, 8HUM and CypC4KO mice were administered daily doses of
SJW and on day 3 dosed with S-acenocoumarol, with one group of
8HUMmice coadministered with the CYP2C9 inhibitor sulfaphenazole
(Fig. 6B). S-acenocoumarol AUCwas increased 8.7-fold in 8HUMmice
treated with sulfaphenazole compared with vehicle-treated mice (20086
159 vs. 230 6 30 hour*ng/ml), consistent with CYP2C9 inhibition in
8HUM mice by sulfaphenazole. The PK profile for S-acenocoumarol in
the sulfaphenazole-treated 8HUM mice was essentially identical to that
in CypC4KO mice (AUC 2520 6 214 hour*ng/ml), suggesting almost
complete inhibition of CYP2C9 in 8Hum mice (Fig. 6B).
As SJW is a potent inducer of CYP3A4 expression in 8HUM mice
at levels similar to human exposure, we investigated the effects of
this preparation and the pharmacologically active constituent hyperforin
on dabrafenib clearance. Dabrafenib pharmacokinetics were de-
termined 2 days after treatment with these preparations. Treatment
with either SJW or hyperforin decreased the AUC of dabrafenib by
69% and 65%, respectively (Fig. 7A; Table 3). Hepatic CYP3A4
levels in the animals from this study are shown in Fig. 7B. Interestingly,
high levels of CYP3A4 expression were observed in animals not
pretreated with either SJW or hyperforin, indicating that dabrafenib
in its own right is a CYP3A4 inducer. This is consistent with the report
that this compound is a CYP3A4 inducer in man (Lawrence et al., 2014;
Puszkiel et al., 2019). Murine Cyp2b10 was also induced weakly by
dabrafenib.
As the dose of dabrafenib used can be extrapolated to that used in
patients, we investigated its capacity to alter the pharmacokinetics of the
CYP3A4 substrate midazolam. Pretreatment with dabrafenib markedly
increased midazolam clearance compared with vehicle-treated animals,
AUCall values decreasing to 91 6 15 from 462 6 70 hour*mg/ml,
respectively (Fig. 8A).
Western immunoblot analysis of samples from this experiment
showed induction of CYP3A4, which was most marked 24 hours after
the final dose of dabrafenib (Dab vs. Dab + MDZ; Fig. 8B). No marked
induction of the other human P450s in the 8HUM was observed,
although some induction of murine Cyp2b10 was detected. Dabrafenib
significantly increased total hepatic microsomal P450 levels, methyox-
yresorufin O-demethylation, dextromethorphan O-demethylation, and
7-benylfluorescein O-debenzylation activities 24 hours after the last
dabrafenib dose and at the start of the PK profiling (Fig. 8C). The most
marked effect of dabrafenibwas on 7-benylfluoresceinO-debenzylation,
which was increased approximately 5.5-fold 24 hours after the second
dabrafenib dose and remained elevated (at about twice control values)
24 hours later.
Relation of Drug/Drug Interactions Observed in 8HUM Mice to
Clinical Measurements. We used the experimental data obtained us-
ing the 8HUM model to evaluate how closely it predicted clinically
observed drug/drug interactions. In 8HUMmice a ketoconazole dose of
35 mg/kg is equivalent to a dose 200 mg/70 kg body weight in man, on
the basis of the body surface area normalization method (Reagan-Shaw
et al., 2008). In a healthy volunteer study, a single dose of 200 mg
ketoconazole resulted in an;5-fold increase of midazolam AUC when
given 2 hours prior to midazolam (McCrea et al., 1999). This was in
close agreement with the 4.7-fold increase in midazolam AUC observed
in 8HUM mice when the equivalent dose of ketoconazole was admin-
istered (Supplemental Table 1).
The interaction of debrisoquine with quinidine given as a single dose
in man has not been reported. We therefore compared the inhibitory
effect of quinidine on the PKs of debrisoquine in 8HUM to that of
desipramine in man because both compounds have a similar fraction
metabolized (fm) in the corresponding species (VandenBrink et al.,
2012). Quinidine increased debrisoquine AUC 16.7-fold compared with
vehicle-treated 8HUM mice. Although the AUC ratio was 8.1-fold
higher compared with the SJW-treated group, this reduction was
possibly the result of suppression of CYP2D6 expression by PXR
ligands in the humanized mice (Scheer et al., 2015). The latter fold
change in AUC corresponds to a CYP2D6 fm of 0.88 for debrisoquine
(eq. 1), assuming complete inhibition of CYP2D6 by the quinidine. In
man desipramine has a CYP2D6 fm of 0.88 (VandenBrink et al., 2012).
Administration of 200 mg quinidine resulted in a 7.5-fold increase of
desipramine AUC in man (Brøsen and Gram, 1989), which was extremely
close to 8.1-fold increase of debrisoquine AUC in eight HUM mice after
coadministrationwith 30mg/kg quinidine. The 30-mg/kg quinidine dose
in mice is equivalent to 170 mg/70 kg body weight man (Reagan-Shaw
et al., 2008).
fm ¼ 12 1AUCR ð1Þ
The interaction of S-acenocoumarol with sulfaphenazole in man has not
been reported, so we used the effect of sulfaphenazole on tolbutamide
pharmacokinetics (Veronese et al., 1990) to predict the S-acenocoumarol
AUC increase in man. The tolbutamide AUCR (eq. 2) was related
to sulfaphenazole concentration and tolbutamide fraction metabolized
Fig. 3. Effect of rifampicin and ketoconazole on dabrafenib pharmacokinetics. (A)
Adult female 8HUM mice (n = 3) were treated with vehicle (corn oil, open circles)
or rifampicin (10 mg/kg, closed circles) intraperitoneally daily for 3 days, with one
of the latter groups receiving a dose of the CYP3A4 inhibitor ketoconazole (20 mg/kg
PO, open triangles) 30 minutes before all groups were administered dabrafenib
(10 mg/kg, PO), and PK profiling was carried out as described in Materials and
Methods. (B) Pharmacokinetic parameters from the profiles shown in (A). Data
shown are mean 6 S.D. *P # 0.05; **P # 0.01; ***P # 0.001 for vehicle vs.
rifampicin and rifampicin vs. rifampicin + ketoconazole, t test. †P # 0.05; ††P #
0.01; for Vehicle vs. rifampicin + ketoconazole, t test.
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by CYP2C9 using the published reverse inhibition component of the
“combined model” of drug-drug interaction (Fahmi et al., 2009).
AUCR ¼ AUCinh
AUC
¼ 1fm
1þ½IKi
þ ð12 fmÞ
ð2Þ
AUCR is the ratio of the drug area under the curve in the presence of
inhibitor (AUCinh) to that without the inhibitor (AUC); [I] is the
concentration of inhibitor; Ki is the dissociation constant for enzyme-
inhibitor complex; fm is the fraction of the drug metabolized by the
inhibited enzyme. Equation 2 can be rearranged to:
½I
Ki
¼ fm1
AUCR2 1þ fm
2 1 ð3Þ
Perkins et al. (2018) estimated the fraction of tolbutamide metabolized
by CYP2C9 to be 0.85 and the AUCR has been reported to be 5.3
(Veronese et al., 1990). Using the values reported in the above studies in
eq. 3 gave an [I]/K value of 21 for sulfaphenazole. The fraction of S-
acenocoumarol metabolized by CYP2C9 was calculated from the
AUCR value of 16.3 for S-acenocoumarol in CYP2C9 extensive versus
poor metabolizers (Thijssen et al., 2001) as shown in Eq. 4:
fm ¼ 12 116:3 ¼ 0:94 ð4Þ
By applying the dose of sulfaphenazole used in the tolbutamide study
(Veronese et al., 1990) to predict its effect on S-acenocoumarol AUC in
man, we used the [I]/Ki value of 21 in eq. 4 together with 0.94 as a
fraction metabolized ( fm).
AUCR ¼ 1fm
1þ ½IKi
þ ð12 fmÞ
¼ 10:94
ð1þ 21Þ þ ð12 0:94Þ
¼ 9:73 ð5Þ
The predicted AUCR in man (9.73 from eq. 5) was close to that observed
in 8HUM mice (8.72). It should be noted that 8HUM mice received a
single dose of 88 mg/kg sulfaphenazole, equivalent to a single dose of
500 mg/70 kg human (Reagan-Shaw et al., 2008), whereas in the vol-
unteer study sulfaphenazole was given every 12 hour at a dose 500 mg
for 48 hours. However, semi–physiologically based pharmacokinetic
modeling suggested that the inhibitory effect of sulfaphenazole given at
multiple doses would not significantly differ from a single inhibitor
administration of 500 mg, because of the very high inhibition
potency and low elimination rate of this CYP2C9 inhibitor (Kanamitsu
et al., 2000). Indeed, chronic administration of 1 g sulfaphenazole
inhibited tolbutamide elimination to an extent like that of a single dose
of this compound (Pond et al., 1977). Thus, multiple 500-mg doses of
sulfaphenazole should produce a similar AUCR for S-acenocoumarol in
man as a single dose, which allows comparison of the observed 8HUM
data to that predicted in man.
Discussion
The 8HUM model probably represents one of the most complex
humanized transgenic models generated to date in that 35 murine genes
were substituted for their human counterparts. We show that 8HUM
mice can reflect many of the characteristics of human drug metabo-
lism and disposition and accurately predict drug-drug interactions
in man. The 8HUM line has significant advantages over previously
A
C
B
Fig. 4. Effect of rifampicin and b-naphthoflavone on osimertinib pharmacokinetics. Adult female 8HUM mice (n = 3) were fed either normal RM1 diet (open circles), RM1
diet with rifampicin (RIF; equivalent dose 10 mg/kg, closed circles) for 3 days or RM1 diet with rifampicin (equivalent dose 10 mg/kg) and administered b-naphthoflavone
intraperitoneally (BNF; 80 mg/kg, open squares) daily for 3 days, and on day 4 were administered osimertinib by oral gavage at a dose of 25 mg/kg, and PK profiling of
osimertinib (A) and metabolites (B) was carried out as described inMaterials and Methods. Osimertinib structure and sites of metabolism in humans (C) are also shown. Data
shown are mean 6 S.D.
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Fig. 5. Pharmacokinetics of probe drugs in 8HUM mice treated with St. John’s Wort with and without P450 inhibitors. Female 8HUM mice were treated with vehicle (open
circles, n = 5), St. John’s Wort (closed circles, n = 3), and SJW and ketoconazole and quinidine (open squares, SJW + inhibitor, n = 3) before being dosed with a drug cassette
and a PK profile carried out as detailed in Materials and Methods for caffeine, debrisoquine, and midazolam. Data shown are mean 6 S.D.
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humanized models in that the potential confounding effects of murine
P450 enzymes, including compensatory changes in expression on drug
disposition, have to a large degree been eliminated (van Waterschoot
et al., 2008; Scheer et al., 2015; Bissig et al., 2018), and the relative im-
portance of human P450s from different gene subfamilies in the dispo-
sition of a compound can be assessed in a single model, as shown here
for osimertinib (MacLeod et al., 2018).
Some of the P450s, notably CYP3A4, were expressed off the human
promoter, allowing the level of hepatic CYP3A4 to be regulated by the
application of CAR or PXR activators and facilitating investigation into
the relationship between the variability in CYP3A4 expression and drug
efficacy or toxicity. CYP1A1 and CYP1A2 expression can also be
regulated through the application of aryl hydrocarbon receptor activators
such as BNF. We have recently shown that CYP1A1 is constitutively
expressed at extremely low levels in all tissues of CYP1A1/1A2-humanized
mice, which was one of the founder lines used to create the 8HUM line.
CYP1A1 was significantly induced to high levels in the liver and lungs,
and to a lesser degree in the gastrointestinal tract and kidney, of
CYP1A1/1A2-humanized mice (manuscript in preparation). It is in-
teresting that CYP3A4 was expressed constitutively in the gastrointes-
tinal tract but not in the livers of males and at a low level in females. By
comparing drug pharmacokinetics with and without pretreatment with
a PXR activator and with and without a specific CYP3A4 inhibitor, the
relative role of gastrointestinal versus hepatic drug metabolism in drug
bioavailability can be established. We show that a number of drugs
known clinically to induce CYP3A4 expression in patients also induce
in the 8HUM model. It has been previously shown, using simpler hu-
manized CAR/PXR models, that compounds such as RIF, CITCO,
TCPOBOP, and dexamethasone exhibit profound species differences
in the activation of these transcription factors. Such effects can con-
found the extrapolation of preclinical studies to man (Scheer et al., 2008,
2010). For example, we show here that dexamethasone, a potent murine
activator of Car/Pxr at a dose of 10 mg/kg (Hasegawa et al., 2011), does
not activate human CAR/PXR in 8HUM mice at this dose. The 8HUM
can therefore be used to determine PK/PD relationships for CAR/PXR
activation that can then be extrapolated to the clinical situation for single
drugs or drug combinations. Also, drugs in development may not exhibit
efficacy in a murine model owing to activation of murine Car or Pxr,
which does not reflect what will happen inman [see Stanley et al. (2006)].
The antitubercular drug RIF has often been used as a specific potent
activator of human PXR and is also a potent CYP3A4 inducer in
patients. However, RIF was hepatotoxic in the 8HUM model, compro-
mising its utility as a generic CYP3A4 inducer in pharmacokinetic and
drug efficacy studies. Our finding that 8HUM mice are uniquely
susceptible to the toxicity of RIF (no toxic effects were observed in
WT mice even at much higher doses), is intriguing and merits further
investigation to determine its relevance to man. However, it is known
that human PXR modulates the hepatotoxicity associated with RIF and
isoniazid cotherapy via a PXR-mediated alteration of heme biosynthesis;
this has previously been studied in WT, Pxr-null, and hPXR mice
(Li et al., 2013). Through the use of 8HUM mice such toxicities can be
studied against a background that is not only humanized for PXR but
also CAR and all the key human drug-metabolizing P450s. Furthermore,
the early onset of toxicity in this model presents the possibility that, with
further validation, the 8HUM mouse could find utility as a rapid onset
model for the study of drug-induced liver injury.
The 8HUM model has numerous potential applications in the quest
to improve drug therapy both in the development of new drugs and
in improving prescribing practices for currently used drugs (Table 4).
Recent studies have highlighted the dramatic increase in drug pre-
scribing in general practice. In 2010 nearly 20% of individuals over the
age of 70 take 10 or more drugs per day, excluding hospital, herbal, and
over-the-counter medicines, with an extremely high risk of serious drug-
drug interaction (Guthrie et al., 2015). It is impossible to test the
potential consequences of these drug combinations by clinical trial, and
the use of the 8HUM model provides a means to test hypotheses and
predict clinical outcomes at an experimental level. This is also the case in
the design of clinical trials, in which drug combinations are increasingly
Fig. 6. S-Acenocoumarol is a specific CYP2C9 probe drug in
humanized mice. (A) In vitro microsomal stability assay. Liver
microsomes from wild-type (open circles), CYP2C9 (open squares),
Cyp2cKO (closed circles), Cyp2c/Cyp2d/Cyp3aKO (closed triangles),
and hepatic P450 reductase null (HRN) (closed squares) mice were
incubated with S-acenocoumarol and disappearance of drug monitored
over time as described in Materials and Methods. Wild-type liver
microsomes without NADPH (open triangles) were included as a
control group. (B) Pharmacokinetics of S-acenocoumarol in 8HUM
and CypC4KO mice. Female 8HUM and CypC4KO mice (n = 3)
were treated with SJW and then administered S-acenocoumarol
individually (open circles) or in combination with sulfaphenazole
(closed circles) before PK profiling for S-acenocoumarol as described in
Materials and Methods. 8HUM mice treated with SJW alone (open
circles), 8HUM mice treated with SJW and sulfaphenazole (SPZ;
closed circles), and CypC4KO mice were treated with SJW followed by
S-acenocoumarol alone (open squares). Values show are mean 6 S.D.
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being used, and particularly so in the treatment of cancer, where the
numerous possible drug combinations involving targeted antitumor
agents [most of which are P450 substrates and as shown here also PXR
agonists (Zanger and Schwab, 2013)] are being tested to increase
efficacy and delay the onset of drug resistance.
Using the 8HUMmodel, drug exposures are obtained that are close to
those observed in man. We also show that human metabolites are
generated and that drug-drug interactions involving P450-P450 or
P450-CAR/PXR can be evaluated. The model can therefore be applied
to the more informed design of complex clinical trials in a manner that
increases the probability of a positive outcome. Our studies with
dabrafenib and osimertinib exemplify these points. For osimertinib the
half-life is 3.5 hours inWTmice, 20 hours in 8HUMmice, and 55 hours
in patients (Cross et al., 2014). All the known human metabolites are
produced, and the major murine osimertinib metabolite [N-oxidation,
OH-2 (MacLeod et al., 2018)] responsible for the rapid clearance inmice
is produced at much lower levels in 8HUM mice. We have shown that
dabrafenib at clinically relevant doses is a potent PXR activator and
CYP3A4 inducer. The predicted clinical consequence is that it will
induce its own metabolism, resulting in reduced exposure; indeed, re-
ductions in the half-life (from 4.2 to 2.1 hours) and AUC0-t (from
9359 to 6545 hour*ng/ml) have been reported in patients whose blood
levels of dabrafenib were measured on days 1 and 18 of treatment at
150 mg twice per day (Suttle et al., 2015). In addition, dabrafenib
probably alters the metabolism of other CYP3A4 or MDR1 drugs used
concomitantly, such as glucocorticoids.
In the light of RIF hepatotoxicity, we identified SJW as a potent,
nontoxic PXR activator to use as a generic inducer of hepatic CYP3A4.
Interestingly, the hyperforin content of our SJW extract (6.9–9.6 mg/kg;
seeMaterials andMethods) was very like that of the hyperforin we used
(10.7 mg/kg), and both significantly reduced dabrafenib exposure to
similar extents, as reflected in several PK parameters, demonstrating the
potential effect on circulating dabrafenib levels.
Although the prediction of human PK parameters from in vitro
experiments has markedly decreased the number of new chemical
entities failing clinical trials, preclinical methods still need improvement
(Kola and Landis, 2004). The estimation of in vivo human clearance
from in vitro data has a tendency to significantly under-predict (Hallifax
and Houston, 2009; Hallifax et al., 2010;Wood et al., 2017), whereas the
in vitro approach tends to over-predict the magnitude of drug-drug
interactions in vivo (Vieira et al., 2014). Animal studies for the
preclinical assessment of potential drug-drug interactions are hindered
by significant species differences in metabolism and the consequential
difference in fraction of drug metabolized. For example, for the human
CYP2D6-specific substrate bufuralol, wild-type mice are rapid metab-
olizers, whereas for another CYP2D6-specific substrate, debrisoquine,
wild-type mice have the profile of slow metabolizers (Scheer et al.,
2012b). Humanization for individual cytochrome P450s or even for
entire P450 clusters does not solve the problem of the effects of enzymes
from other P450 subfamilies (Perloff et al., 2000; vanWaterschoot et al.,
2008). The 8HUM model has all major mouse cytochrome P450s
replaced by their human orthologs and thus has the potential to be a tool
with improved accuracy for prediction of drug-drug interaction in the
preclinical stage of drug development. The issue of defining the fraction
of drug metabolized for such calculations can be resolved through the
use of the CypC4KO model as illustrated for S-acenocoumarol.
Over the last 30 years advances in our understanding of drug
metabolism has markedly improved the drug development process and
enhanced our understanding of drug-drug interactions. In this regard, a
variety of informative in silico and laboratory-basedmodel systems have
TABLE 3
Effect of St. John’s Wort and hyperforin on dabrafenib clearance in the 8HUM mouse
Animal treatments and enzyme activity measurements were carried out as described in Materials and Methods. Data shown are mean 6
S.D. from a minimum of three determinations.
Vehicle St. John’s Wort Hyperforin
Cmax (mg/ml) 16.7 6 2.9 10.2 6 1.9** 10.9 6 1
Terminal half-life (h) 1.9 6 1.22 1.8 6 0.9 1.2 6 0.1
AUCinf(obs) (h*mg/ml) 76 6 3.2 24.2 6 3.3**** 26.7 6 5.2***
CL/F(obs) (ml/h per kilogram) 132 6 5.5 419 6 58**** 383 6 76**
Total hepatic P450 (pmol/mg protein) 286 6 39 314 6 80 276 6 28
n 4 4 2
**P , 0.01, ***P , 0.001, ****P , 0.0001 for vehicle vs. SJW or hyperforin, t test.
Fig. 7. Effect of St. John’s Wort and hyperforin on pharmacokinetics. (A) Female
8HUM mice (n = 2–4) were treated with vehicle (open circles), St. John’s Wort
(closed circles) or hyperforin (HYP; open squares) for 2 days as described before
being dosed with dabrafenib for PK profiling as described in the Materials and
Methods. Data are shown as mean 6 S.D. (B) Liver microsomes from the 8HUM
mice treated in (A) with vehicle, St. John’s Wort (SJW), or hyperforin (HYP), and
also subject to dabrafenib PK profiling, were immunoblotted against CYP3A4 and
Cyp2b10. Arrow indicates position of Cyp2b10 band. GRP78 was used as a loading
control.
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been developed to predict drug exposure and drug-drug interactions in
man with varying degrees of success. Researchers in industry depend
increasingly on in silico approaches such as simulation tools and the
SimCyp family of modeling; however, it is still recognized that the
prediction of drug disposition from in vitro and in silico data needs
fundamental improvement (Wood et al., 2017). Through the use of more
complex humanized models, many of the shortcomings of simpler
humanized models, e.g., redundancy between murine gene families, is
avoided. However, it is acknowledged that, by definition, no model is
perfect and that factors such as species differences in plasma protein
binding and biliary elimination will not be addressed necessarily in a
model such as the 8HUM, although with regard to the former an
extensive study showed good correlation between protein binding in
humans, rats, mice, and dogs for .500 drugs (Colclough et al., 2014).
With regard to the 8HUM model, it should be noted that a number
of murine P450s remain, e.g., Cyp2a, Cyp2b, Cyp2e gene families;
however, their roles in drug disposition can be evaluated using CypC4
KO and HRN mice. It is also worthy of note that other pathways in the
8HUM model have not been humanized, e.g., drug transporters such as
Abcb1/b2, Abcg1; however, species differences in these transporters are
poorly defined (Chu et al., 2013) and their role in drug disposition can
be established using knockout animals whose transporters have been
deleted or through the use of inhibitors whose specificity is enhanced
when used in conjunction with the CypC4 KO model.
The sophisticated 8HUM model described here complements these
approaches by providing a powerful approach for establishing the role of
the human P450 system in drug disposition and defining the role of other
pathways of drug elimination, such as thosemediated by drug transporters
and/or phase 2 enzymes. It has significant potential in predicting human
responses to drugs, extrapolating drug efficacy studies to man, addressing
cases where human metabolism differs markedly from that in conven-
tional animal models, and personalizing the treatment of disease. To
further improve the versatility of the model for drug efficacy studies and
to establish PK/PD relationships, 8HUM versions of murine disease
TABLE 4
Applications of the 8HUM mouse
Define the role of cytochrome P450s in vivo drug/xenobiotic disposition (CypC4 KO)
Improve the predictive power of drug efficacy studies with more human-like PK
and in vivo generation of human drug metabolites
More accurate predictions of individual patient responses to targeted anticancer
drugs
Understanding how variability in P450 isozymes affects drug efficacy
Potential application in the study of drug-induced toxicity
Predicting potential drug-drug interactions for single and complex drug mixtures
and how these could be circumvented
Studying the interaction of drugs with herbal medicines and environmental
agents
Defining PK/PD relationships for chemopreventive agents
Improve in silico algorithms for extrapolating laboratory data to the clinic
Fig. 8. Effect of dabrafenib on midazolam pharmacokinetics in
8HUM mice. Adult female 8HUM mice (n = 3) were treated with
vehicle or dabrafenib (10 mg/kg) PO daily for 2 days, and on day 3
were administered midazolam (3 mg/kg) PO and PK profiling
carried out as described in Materials and Methods. (A) Pharmaco-
kinetic profiling for midazolam in 8HUM mice receiving either
vehicle (open circles) or dabrafenib (closed triangles). Data shown
are mean 6 S.D. (B) Immunoblotting of liver microsomes from
8HUM mice, untreated or treated as above, against mouse and
human P450 isozymes. Dab, Dabrafenib; MDZ, midazolam;
Unt, untreated; Veh, vehicle. One group of dabrafenib-treated mice
(Dab) were sacrificed on day 3 without exposure to midazolam to
determine the effects of dabrafenib on P450 expression at the start
of the PK profiling. The other samples were collected after the
completion of the PK study 24 hours later. Std, standard, recombinant
human P450 protein or phenobarbital-treated liver microsomes
(Cyp2b10); HLM, human liver microsomes. (C) Effects of dabrafenib
treatment on hepatic cytochrome P450-related activities in liver
microsomes from 8HUM mice 24 and 48 hours after drug treatment.
Data shown are mean 6 S.D. Unpaired t test (two tailed P values)
statistically significant compared with vehicle **P # 0.01; ****P #
0.0001 for vehicle vs. dabrafenib at 24 or 48 hours, t test.
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models could also be created (e.g., using CRISPR technology). Such
models will be of value in determining how variability in drug exposure
affects drug responses toxicities, facilitating studies into the personal-
ization of drug treatment. In this regard, we have a particular interest in
the use of themodels for the personalized treatment of cancer to improve
the predictive power of patient-derived xenograft drug sensitivity studies
(Hidalgo et al., 2014). We are currently making an immunodeficient
version of the 8HUM model for this purpose.
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